« Return to News | Clinical Intelligence

Oncolytics Biotech launches phase II study in prostate cancer

Tuesday, February 28, 2012 06:08 AM

Calgary, Cananda-based Oncolytics Biotech has collaborated with the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, to conduct a randomized phase II study of Reolysin in patients with recurrent or metastatic castration resistant prostate cancer.

The phase II study will build on both companies’ early preclinical and clinical prostate cancer work, as well as their growing understanding of Reolysin in combination with approved chemotherapeutic agents, according to Dr. Brad Thompson, president and CEO of Oncolytics.

The study will be an open-label, randomized, non-blinded, phase II clinical study of Reolysin given in combination with docetaxel versus docetaxel alone. Approximately 40 response evaluable patients will be enrolled in each arm.

"Third party sponsored trials remain an important part of our overall clinical strategy,” said Thompson. “We are pleased to be conducting another randomized study, especially in Canada, with an experienced and capable group like the NCIC CTG.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.